Opinion
Video
Marcia Brose, MD, examines data from the COSMIC-311 study, emphasizing the importance of promptly initiating second-line therapy for patients who have progressed on first-line treatments.
Advanced Systemic Mastocytosis: Expert Insight into Epidemiology, Diagnosis, and Treatment
Orca-T Is a Safe Addition to HSCT-RIC in Advanced Hematologic Malignancies
Enfortumab Vedotin/Pembrolizumab Elicits Radiographic Responses in Primary UTUC Lesions
Ruxolitinib Plus SOC Prophylaxis Is Associated With Lower Rates of GVHD in Myelofibrosis
Updated CheckMate-274 Data Further Support Adjuvant Nivolumab as SOC for High-Risk MIUC